Stephen Harrap

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.